Trial Profile
Food-effect Study of Weekly Administration of (bi-)Daily Oral Docetaxel (ModraDoc006) in Combination With Ritonavir
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Docetaxel/ritonavir (Primary) ; Ritonavir (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Modra Pharmaceuticals
- 19 Jan 2021 Status changed from active, no longer recruiting to completed as per resultspublished in the Drugs in R and D.
- 19 Jan 2021 Results published in the Drugs in R and D.
- 25 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.